Researchers call for ‘evidence-based’ driving restrictions for patients treated with CAR-T therapy
Driving restrictions for blood cancer patients undergoing chimeric antigen receptor (CAR)-T cell therapy may need reconsideration, according to research presented by Rahul Banerjee, MD, FACP, of the University of Washington Fred Hutchinson Cancer Center, at the 66th ASH Annual Meeting and Exposition. Current package inserts from the US Food and Drug Administration universally recommend blood cancer patients refrain from driving for eight weeks post-infusion, yet there is no clear evidence to justify these restrictions, the investigators wrote. Dr. Banerjee and colleagues specifically highlighted CAR-T therapies used to treat multiple myeloma such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which use 4-1BB costimulatory domains. The 4-1BB domain is known to cause fewer serious side effects after the first month compared with other types. Dr. Banerjee and colleagues analyzed data from 553 CAR-T recipients who had received either cilta-cel (n=224) or ide
